Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€20.20

€20.20

-3.810%
-0.8
-3.810%
€31.57
 
25.03.24 / Tradegate WKN: A1W96L / Symbol: XNCR / Name: Xencor / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Xencor Inc. Stock

Xencor Inc. took a tumble today and lost -€0.800 (-3.810%).
We see a rather positive sentiment for Xencor Inc. with 8 Buy predictions and 1 Sell predictions.
As a result the target price of 31 € shows a very positive potential of 53.47% compared to the current price of 20.2 € for Xencor Inc..

Pros and Cons of Xencor Inc. in the next few years

Pros
?
G***** c******* t* c**********
?
M***** P*******
?
C******** o* t** e**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Xencor Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Xencor Inc. -3.810% -5.607% -17.886% -21.705% -1.942% -43.575% -
Ironwood Pharmaceuticals 2.600% -3.049% -42.391% -20.785% -23.558% -11.667% -31.701%
Novocure Ltd 0.930% 7.378% -10.971% -75.204% -6.200% -87.619% -
Iovance Biotherapeutics Inc. 1.540% -4.442% -19.187% 128.293% 66.688% -47.104% -

Comments

Prediction Buy
Perf. (%) -3.81%
Target price 29.530
Change
Ends at 28.02.25

Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $32.00 price target on the stock.
Ratings data for XNCR provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -3.81%
Target price 31.365
Change
Ends at 28.02.25

Xencor, Inc. (NASDAQ: XNCR) had its price target lowered by analysts at BMO Capital Markets from $38.00 to $34.00. They now have an "outperform" rating on the stock.
Ratings data for XNCR provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -4.72%
Target price 31.396
Change
Ends at 28.02.25

Xencor, Inc. (NASDAQ: XNCR) had its price target lowered by analysts at Wedbush from $36.00 to $34.00. They now have an "outperform" rating on the stock.
Ratings data for XNCR provided by MarketBeat
Show more

News

Xencor to Present at Upcoming Investor Conferences: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present at Upcoming Investor Conferences


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company

Xencor Reports Fourth Quarter and Full Year 2023 Financial Results: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for

Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it